Chikuba K, Saito T, Uchino S, Inomata M, Kobayashi M
First Department of Surgery, Oita Medical University.
Jpn J Clin Oncol. 1995 Dec;25(6):229-33.
Amplification of the hst-1 gene was examined in 112 neoplastic lesions from 27 patients with esophageal carcinoma. Ninety specimens were separately obtained from two or more sections of each individual primary tumor with DNA stem line heterogeneity and 22 specimens were obtained from metastatic lymph node lesions. The assessment was that hst-1 gene amplification within each individual primary tumor was identical in all 27 cases (100%) and that the intensity of amplification in the primary tumor matched that in the metastatic lesion in 18 of 22 cases (82%). When we examined 33 endoscopic biopsy specimens from esophageal carcinoma in the same manner, the intensity of hst-1 gene amplification in the specimens was similar to that obtained in surgical specimens from 26 of the 33 patients (79%). These results suggest that hst-1 gene amplification might occur in a homogeneous manner as a relatively early genetic event prior to lymph node metastasis, and that therefore, prior to surgical treatment, it can be evaluated from a single biopsy specimen.
对27例食管癌患者的112个肿瘤性病变进行了hst - 1基因扩增检测。90个样本分别取自每个具有DNA干细胞系异质性的原发性肿瘤的两个或更多切片,22个样本取自转移性淋巴结病变。评估结果显示,在所有27例病例(100%)中,每个原发性肿瘤内的hst - 1基因扩增是相同的,并且在22例中的18例(82%)中,原发性肿瘤中的扩增强度与转移病变中的扩增强度相匹配。当我们以同样的方式检测33例食管癌的内镜活检样本时,33例患者中的26例(79%)样本中的hst - 1基因扩增强度与手术样本中的相似。这些结果表明,hst - 1基因扩增可能以一种均匀的方式作为淋巴结转移之前相对早期的遗传事件发生,因此,在手术治疗之前,可以从单个活检样本中进行评估。